Mecasermin rinfabate
- Generic Name
- Mecasermin rinfabate
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 478166-15-3
- Unique Ingredient Identifier
- NZ8M50KKRG
- Background
Mecasermin rinfabate is approved for severe primary insulin-like growth factor (IGF) deficiency or in patients with GH gene deletion who have developed antibodies to growth hormone (GH). Mecasermin rinfabate is similar to Mecasermin in that both drugs contain recombinant DNA origin insulin-like growth factor 1 (IGF-1). Mecasermin rinfabate however, is alread...
- Indication
Mecasermin rinfabate was approved for treatment of severe primary insulin-like growth factor (IGF) deficiency or in patients with GH gene deletion who have developed antibodies to growth hormone (GH).
Severe primary IGF-1 deficiency is defined by:
A) height standard deviation (SD) score less than or equal to 3 SD below normal
...
- Associated Conditions
- Growth Hormone Gene Deletion, Primary Insulin-like Growth Factor-1 Deficiency
- Associated Therapies
- -
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
- First Posted Date
- 2010-03-31
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Shire
- Target Recruit Count
- 121
- Registration Number
- NCT01096784
- Locations
- ๐บ๐ธ
Georgia Regents Medical Center, Augusta, Georgia, United States
๐บ๐ธVidant Medical Center, Greenville, North Carolina, United States
๐บ๐ธWest Virginia University Hospital, Morgantown, West Virginia, United States
Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
- Conditions
- Interventions
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 69
- Registration Number
- NCT00577577
- Locations
- ๐บ๐ธ
University of Texas Health Science Center, San Antonio, Texas, United States
๐บ๐ธUniversity of Utah, Salt Lake City, Utah, United States
๐บ๐ธOhio State University Medical Center, Columbus, Ohio, United States
IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome
- Conditions
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2012-09-13
- Lead Sponsor
- Insmed Incorporated
- Registration Number
- NCT00368173
- Locations
- ๐ฎ๐น
Maria Carolina Salerno, Naples, Italy
๐ง๐ทDr. Durval Damiani, Sao Paulo, Brazil
๐ฆ๐บDr. Bruce King, Newcastle, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.